Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Ludwigshafen
Clinical trial register · Germany

Clinical Trials in Ludwigshafen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5081 matching records held by the registry are in this view. Synced 13 Nov 2026, 03:18 UTC
5081
Studies in scope
all four open statuses
2880
Recruiting now
open to new participants
985
Lead sponsors
across recruiting studies
Top sites
Berlin 1591 Hamburg 896 Essen 767 Dresden 717 Heidelberg 626

Trials with a site in Ludwigshafen

28 of 5081 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Not yet open
Novo Nordisk A/S
Phase 3
450
Bad Mergentheim, Berlin, Ludwigshafen, Mainz, Münster, Pirna, Pohlheim
2026-11-10
Recruiting
Eli Lilly and Company
Phase 2
60
Berlin, Dachau, Halle, Ludwigshafen, Ulm
2026-05-04
Recruiting
Eli Lilly and Company
Phase 2
60
Berlin, Dachau, Halle, Ludwigshafen, Ulm
2026-05-04
Recruiting
Novartis Pharmaceuticals
Phase 2
272
Ludwigshafen, Bonn, Münster, Tübingen
2026-03-09
Recruiting
MMI (Medical Microinstruments, Inc.)
Not applicable
100
Ludwigshafen
2025-12-18
Active, closed
Alexion Pharmaceuticals, Inc.
Phase 2
78
Berlin, Göttingen, Ludwigshafen
2025-11-26
Active, closed
Sanofi
Phase 2
60
Frankfurt, Ludwigshafen, Tübingen, Ulm
2025-10-14
Recruiting
Takeda
Phase 3
396
Berlin, Frankfurt am Main, Halle, Jena, Kiel, Ludwigshafen, Mannheim
2025-01-02
Recruiting
Novartis Pharmaceuticals
Observational
500
Konstanz, Stuttgart, Munich, Regensburg, Würzburg, Cottbus, Frankfurt (Oder), Ludwigshafen
2024-09-04
Active, closed
Iptacopan in Patients With ANCA Associated Vasculitis
NCT06388941Anti-Neutrophil Cytoplasm Antibodies (ANCA) Associated Vasculitis
Novartis Pharmaceuticals
Phase 2
84
Kirchheim unter Teck, Munich, Ludwigshafen, Berlin, Mainz
2024-08-05
Active, closed
Takeda
Phase 2
213
Frankfurt am Main, Hamburg, Heidelberg, Kiel, Ludwigshafen, Tübingen, Ulm
2024-03-29
Recruiting
Takeda
Phase 2
268
Frankfurt, Frankfurt am Main, Kiel, Ludwigshafen, Mannheim, Tübingen, Ulm
2024-03-05
Active, closed
Novartis Pharmaceuticals
Phase 3
612
Freiburg im Breisgau, Würzburg, Ludwigshafen, Cologne, Dresden, Berlin, Erlangen, Hanover
2023-10-27
Recruiting
The Lymphoma Academic Research Organisation
Phase 3
260
Amberg, Berlin, Kiel, Ludwigshafen, Regensburg, Stuttgart, Trier, Ulm
2023-09-05
Recruiting
Anthos Therapeutics, Inc.
Phase 3
2,500
Altenburg, Berlin, Dresden, Hamburg, Hanover, Ludwigshafen, Markkleeberg, Paderborn
2022-12-27
Active, closed
Sanofi
Phase 2
187
Düsseldorf, Fulda, Kiel, Ludwigshafen, Ulm
2022-11-25
Active, closed
Dentsply Sirona Implants and Consumables
Not applicable
139
Ludwigshafen, Olsberg, Oppenheim
2022-09-22
Active, closed
Hoffmann-La Roche
Phase 3
451
Bonn, Cologne, Cottbus, Freiburg im Breisgau, Hamburg, Ludwigshafen, München, Münster
2021-07-14
Active, closed
Helios Health Institute GmbH
Not applicable
250
Bremen, Dresden, Düsseldorf, Essen, Hamburg, Leipzig, Ludwigshafen, Lübeck
2021-07-05
Recruiting
King's College Hospital NHS Trust
Phase 3
210
Bonn, Hamburg, Ludwigshafen, München, Münster, Sulzbach, Ulm, Würzburg
2021-04-16
Active, closed
Combination of Ranibizumab and Targeted Laser Photocoagulation
NCT04444492Central Retinal Vein Occlusion With Macular Edema
University of Giessen
Phase 3
88
Freiburg im Breisgau, Giessen, Hanover, Leipzig, Ludwigshafen, Marburg, München, Münster
2020-08-25
Active, closed
Comparison of Vessel-FFR Versus FFR in Intermediate Coronary Stenoses
NCT03497637Coronary Artery Disease, Coronary Artery Stenoses
Helios Health Institute GmbH
Not applicable
1,054
Dresden, Erlangen, Essen, Giessen, Leipzig, Ludwigshafen, Neuss
2020-06-20
Active, closed
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
NCT04083599Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Melanoma
Genmab
Phase 1/2
350
Heidelberg, Ludwigshafen, Mainz, Mannheim, Würzburg
2019-09-17
Active, closed
Dentsply Sirona Implants and Consumables
Not applicable
160
Ludwigshafen
2019-07-30
Recruiting
Periprosthetic Fracture Registry (PPFx)
NCT03378557Periprosthetic Fractures, Periprosthetic Fracture Around Prosthetic Joint Implant
AO Innovation Translation Center
Observational
600
Berlin, Ludwigshafen, Münster
2018-12-31
Recruiting
Hoffmann-La Roche
Phase 3
1,000
Bonn, Cologne, Cottbus, Freiburg im Breisgau, Hamburg, Ludwigshafen, München, Münster
2018-09-20
Active, closed
Eli Lilly and Company
Phase 3
1,058
Berlin, Brandenburg, Halle, Hamburg, Hanover, Ludwigshafen
2018-07-18
Active, closed
Janssen Biotech, Inc.
Observational
535
Berlin, Dessau Roblau, Halle, Hamburg, Heidelberg, Kiel, Leipzig, Ludwigshafen
2016-12-16
Rows per page Showing 1–28 of 28
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 November 2026. https://priyalifescience.com/clinical-trials-germany/city/ludwigshafen

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,081 studies in total at the last sync on 13 Nov 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 28 of those studies with a site in Ludwigshafen.

How many clinical trials are recruiting in Ludwigshafen?

12 of the 28 studies on this page are recruiting new participants as of the 13 Nov 2026, 03:18 UTC sync. A further 1 have not yet opened recruitment, 15 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Ludwigshafen), 28 studies
PhaseStudiesRecruitingShare
Phase 310535.7%
Phase 29432.1%
Not applicable5117.9%
Observational3210.7%
Phase 1/2103.6%

Most active sponsors

Lead sponsors with the most studies (Ludwigshafen)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals42
Eli Lilly and Company32
Takeda32
Dentsply Sirona Implants and Consumables20
Helios Health Institute GmbH20
Hoffmann-La Roche21
Sanofi20
Alexion Pharmaceuticals, Inc.10
Anthos Therapeutics, Inc.11
AO Innovation Translation Center11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.